Form 4: Myriad Genetics: Chief Accounting Officer Reports Stock Transaction
SEC Form 4
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On March 25, 2025, Natalie Munk, the Chief Accounting Officer of Myriad Genetics, had 362 shares of common stock withheld by the company to cover tax obligations.
- This transaction occurred in connection with the vesting of restricted stock units.
- The price per share for the transaction was $9.73.
- Following the transaction, Munk directly owns 46,129 shares of Myriad Genetics common stock.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard executive compensation practices and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity related to compensation and tax obligations, which is a common occurrence.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine part of executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/25/2025 | Date of stock transaction (shares withheld for tax obligations). |
| 03/26/2025 | Date of signature on the Form 4 filing. |
Keywords
Myriad Genetics, Natalie Munk, Chief Accounting Officer, Form 4, Stock Transaction, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.